Consano Bio, Inc.
Last verified 2026-05-05. JSON
| Total raised | $34.8M |
|---|---|
| Latest round | Funding round, $34.8M, 2026-03-20 |
| Founded | unknown |
| Headquarters | BURLINGTON, MA |
| Industry | bio |
| Stage | unknown |
| Website | consanobio.com |
Consano Bio is a biotech developing C-1101, a biologic therapy for chronic sciatica caused by lumbosacral radiculopathy. It serves patients with chronic nerve pain whose existing options have failed or are inadequate. The candidate is positioned to be the first non-opioid pharmaceutical that modifies the underlying disease rather than masking pain.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-20 | Funding round | $34.8M | undisclosed |
Detected tech stack
WordPress 7.0, Apache HTTP Server, MonsterInsights 10.2.0, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, DoubleClick Floodlight, WP Rocket, PHP, MySQL, jquery 3., apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $34.8M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $34.8M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | consanobio.com, read 2026-05-05 |
| Description | self-reported | consanobio.com, read 2026-05-05 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $34.8M, 2026-03-20 → Funding round, $34.8M, 2026-03-20, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $34.8M, 2026-03-20 → Funding round, $34.8M, 2026-03-20 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes